ALSO NOTED: Genaera touts Phase II results; Genentech reports big increase in profits; Predicant lines up debt financing; and m

> Genaera reported that a Phase II trial of Evizon with Visudyne demonstrated its safety and vision stabilization for patients with wet, age-related macular degeneration. Release [1]

> The phenomenal success of Avastin and Herceptin for cancer has helped swell Genentech's quarterly net income by 56 percent. Article [2]

> Predicant Biosciences has lined up $7.5 million of debt financing from Hercules Technology Growth Capital. Release [3]

> Boston-based Surface Logix said that an early-stage trial of SLx-2101 for sexual dysfunction shows it was safe and well tolerated and demonstrated signs of pharmacokinetic activity. Release [4]

And Finally… Although still relatively rare in the US, the incidence of liver cancer is rising fast. Article [5]